Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorYavuz, S.
dc.contributor.authorCansu, D.U.
dc.contributor.authorNikolopoulos, D.
dc.contributor.authorCrisafulli, F.
dc.contributor.authorAntunes, A.M.
dc.contributor.authorAdamichou, C.
dc.contributor.authorRönnblom, L.
dc.date.accessioned2020-12-02T18:00:12Z
dc.date.available2020-12-02T18:00:12Z
dc.date.issued2020
dc.identifier.issn0049-0172
dc.identifier.urihttps://doi.org/10.1016/j.semarthrit.2020.02.020
dc.identifier.urihttp://hdl.handle.net/11446/3561
dc.description.abstractObjective: Detailed analysis of hematological manifestations (HM) in systemic lupus erythematosus (SLE) are limited and their clinical impact on disease remain obscure. Here, we aimed to decipher factors associated with different hematological abnormalities in SLE patients and to assess their impact on disease related outcomes. Methods: A dataset (GIPT) originating from SLE patients of six European tertiary centers was assessed. Six-monthly visits of each patient for at least 2 years were registered. the association between hematologic manifestations (HM; per ACR-1997criteria) and clinical/serologic variables, as well as the impact of HM on disease related outcomes (damage, infection and hemorrhage) were explored. Scores on the Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI2K), the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) and events for any infection and hemorrhage were recorded. Results were compared with a cross-sectional, well-characterized SLE dataset from Sweden. Descriptive statistics, the generalized estimating equations (GEE), general linear models (GLM), Cox regression models were applied. Results: We monitored 1425 longitudinal visits in 286 SLE patients with HM (GIPT dataset: 88% female, 95% Caucasian, 68% dsDNA positive). Thrombocytopenia (regression coefficient [95% confidence interval] 1.86[1.1–3.13]) and neurologic involvement (ACR-8) (2.1[1.10–3.89]) were associated with lymphopenia (<1000/mm3); the latter was an independent predictor of organ damage accrual (1.68[1.2–2.62]). These associations were confirmed in an independent dataset of 1348 SLE patients (86% female, 93% Caucasian, 61% dsDNA positive) in Sweden.Severe lymphopenia (<500/mm3) and severe thrombocytopenia (<20 K/mm3) were associated with increased risk for infection (hazard ratio [95% confidence interval] 2.56[1.23–5.31]) and hemorrhage (4.38[2.10–11.1]), respectively, independent of the effect of other predictors. Conclusion: : Lymphopenia in SLE is independently associated with neurologic involvement and organ damage accrual, and thus, may be considered as a marker of severe/progressive disease. © 2020 Elsevier Inc.en_US
dc.description.sponsorshipStiftelsen Konung Gustaf V:s 80-årsfond RAED-AD110 Uppsala Universiteten_US
dc.description.sponsorshipThis project was funded by Turkish Society for Rheumatology (RAED-AD110) and by the Swedish Research Council for Medicine, Swedish Society of Medicine and Ingegerd Johansson donation, Swedish Rheumatism Foundation, King Gustaf V's 80-year Foundation and Uppsala University.en_US
dc.language.isoengen_US
dc.publisherW.B. Saundersen_US
dc.identifier.doi10.1016/j.semarthrit.2020.02.020en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleLymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational studyen_US
dc.typearticleen_US
dc.relation.journalSeminars in Arthritis and Rheumatismen_US
dc.departmentDBÜen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempYavuz, S., Department of Medical Sciences, Division of Rheumatology, Uppsala University, 751 85, Uppsala, Sweden, Sweden, Department of Internal Medicine, Division of Rheumatology, Istanbul Bilim University, Istanbul, Turkey; Cansu, D.U., Department of Rheumatology, Eskişehir Osmangazi University, Eskişehir, Turkey, Turkey; Nikolopoulos, D., Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece, Greece; Crisafulli, F., Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Italy, Italy; Antunes, A.M., Unidade de Doenças Auto-imunes/Serviço Medicina 7.2, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Portugal, Portugal; Adamichou, C., Clinical Immunology and Allergy, Universen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster